The financial investment required to study a condition impacting eight million individuals is virtually identical to the cost of researching an illness that affects merely eight thousand people. The structural design of the trials, the decade it takes to complete them, and the regulatory agencies involved remain exactly the same.
Ultimately, the only factor that shifts is the final audience purchasing the resulting answer.
Because a demographic of eight thousand individuals does not constitute a viable commercial market, people rarely search for those specific solutions. However, while this smaller group may not be a profitable market, they still have the potential to operate collectively as a fund.
@BioAIDevsとのコラボレーションにより、BIOS AI Scientistの最新の機能強化を紹介するライブデモを開催します。このプレゼンテーションでは、深い研究のためのベストプラクティスをカバーし、プランモード、ブランチオフ、ペーパー生成などの新機能を紹介します。また、BIOS APIも強調し、@openclawおよび@cursor_aiとの完全な互換性を持つエージェントに生物医学的ワークフローを追加する方法を説明します。以下の放送に参加してください。